...excellence
and passion

A team of >300 employees
in >30 countries

 

30% R&D

MANAGEMENT TEAM

 

The greatest minds in biotechnology and machine learning are at work at SOPHiA GENETICS, continuously honing our algorithms, offers and services for the benefit of doctors and their patients. About 80% of our organization holds a PhD, ranging anywhere from Cell Biology to Computer Science. This international and dedicated team is the key to our current success and is the promise of an even greater future ahead for us and the world of genomics.

Jurgi Camblong

Chief Executive Officer and Co-founder  

Dr. Jurgi Camblong is a visionary entrepreneur who is pioneering the Data-Driven Medicine movement around the world. He is a Molecular Biologist (published in Cell, Science & Nature), has a PhD in Life Sciences from the University of Geneva, and an EMBA in Management of Technology from EPFL/HEC Lausanne. In 2011, he founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz, and has since successfully been leading the development of the company, listed by the MIT Technology Review amongst the 50 smartest companies in 2017. Dr. Camblong is a member of the Advisory Council on Digital Transformation to the Swiss Federal Government, and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.  

Gioia Althoff

SVP - Genomics Business Area

Gioia Althoff’s entrepreneurial spirit and analytical skills have helped to accelerate the adoption of SOPHiA GENETICS’ AI for clinical genomics ever since she joined the company in 2014. She effectively managed the mature central European markets as a Business Development Manager. Her proven track record led her to subsequently supervise the executive genomic business unit since 2018. She obtained her Docterate in Neuropathology at the Albert-Ludwigs University in Freiburg in Germany and her Master’s degree in Physiology and Neurosciences at the University Louis Pasteur in Strasbourg in France. She built her business acumen by founding a successful family business and obtained a Certificate of Advanced Studies in Biotech, Medtech and the Pharmaceutical Industry at the École polytechnique fédérale de Lausanne (EPFL).

Thierry Colin

SVP - Radiomics Business Area

After several internships at Argonne National Laboratory in Chicago, Thierry Colin defended his PhD in Paris in Applied Mathematics. He then moved to Bordeaux, where he became a University Professor. He established a research team at INRIA Bordeaux working on Mathematical Modelling in oncology in collaboration with the university hospital and with the Institut Bergonié, one of the leading institutions in France in the fight against cancer. The team has produced innovative methods which allow us to make accurate predictions on tumor growth and enable us to track and how patients respond to treatment, using medical imaging and genomic data. During this time Dr. Colin oversaw the research of 25 PhD students. Furthermore, he authored more than 150 scientific papers and was invited by professors from more than 25 university around the world. 

He joined SOPHiA GENETICS in 2018 in order to develop Radiomics applications and coupling them with genomics in order to develop more comprehensive solutions for Data-Driven Medicine.

Esteban Czwan

SVP - Clinical Trials Business Area   

Esteban Czwan is a dynamic business executive experienced in Business Development, Product Management, and Customer Support. Before joining SOPHiA GENETICS in 2015, Esteban worked for Roche Diagnostics where he was responsible for next-generation sequencing support and third-party analytical solutions. Esteban did his doctoral work at the German Cancer Research Center in Heidelberg developing predictive models of tumor progression and therapy response. Esteban obtained his master’s degree in Bioinformatics from Cardiff University and his bachelor’s degree in Computer Science from the University of Illinois at Springfield.

Damien Lapray

SVP - Chief Commercial Officer   

Dr. Damien Lapray joined SOPHiA GENETICS in 2014 as Sales and Business Development Manager of the Nordics. He then served as VP Sales. During that time, he successfully developed SOPHiA GENETICS Integrated Diagnostic Solutions from scratch to help institutions not equipped with a NGS platform benefit from this technology. In September 2016 Damien Lapray was appointed Chief Commercial Officer to lead the whole sales department. Prior to joining SOPHiA GENETICS he obtained a PhD in Neurophysiology from the University of Mainz in Germany and made a successful career in research focusing on neuronal networks within prestigious institutions such as the University of Oxford and the EPFL - Lausanne. Self-driven, he acquired his fighting spirit from a successful sport career where he learned to always push the limits. Surrounded by a very talented team he is accelerating SOPHiA GENETICS development worldwide.

Valentin Matillon

SVP - Chief Financial Officer  

Valentin Matillon joined SOPHiA GENETICS in 2018 as Chief Financial Officer. He is a seasoned finance executive with over 20 years of leadership experience in IT, Telecommunications and MedTech companies. He has held a number of senior finance management positions at SITA, Electronic Arts and Hewlett-Packard, including Group CFO, senior finance director in charge of corporate finance, financial planning & analysis, and performance management programs. Most recently, as senior finance director at the Hobart Group, Valentin led the corporate finance, financing & accounting operations team. 

As CFO, Valentin focuses on increasing shareholder value by driving global financial excellence and long-term sustainability. In addition to leading the Finance organization, Valentin is also in charge of the Legal department and Business Development activities. He received his Finance B.A. from Institut des Hautes Etudes Economiques et Commerciales de Paris and his MS from Ecole Centrale de Paris, France. 

 "It is not the strongest of the species that survives, but the most adaptable" - Charles Darwin

Gaëtan Fraikin

SVP - Chief Marketing Officer  

Gaëtan Fraikin is a global expert in data-driven strategy, marketing and branding of more than 20 years. He joined SOPHiA GENETICS in July 2019 after most recently holding executive positions at leading sequencing brands including Illumina and Roche. Prior to that, he founded and led Audacity, a premier agency that specialized in brand strategy and communication. Gaëtan has a combined MBA in marketing and business engineering from Ecole Des Hautes Etudes Commerciales. He has a history of innovative brand promotion in the fields of health-tech, genomics and wearables for diagnostics, treatment and monitoring in personalized medicine. He also taught Branding and Marketing at San Diego State University. He’s a valued creator through disruptive thinking and unconventional execution, driving accelerated and profitable growth.

Kevin Puylaert

General Manager North America and VP Business Development

Kevin Puylaert is the General Manager of SOPHiA GENETICS’ North American operations and VP Business Development. His focus is on broadening the company’s reach within the clinical research industry across the region while managing business development and partnerships. His commitment and entrepreneurial spirit has been pivotal in accelerating the adoption of SOPHiA AI around the world. Prior to his current role he led the company’s business development activities outside of Europe and was responsible for building sales teams across APAC, LATAM and Africa. Before joining the company, Kevin was a lead Strategic & Development Project Manager at the Clinique Universitaire Saint-Luc in Belgium. He has a Bachelor’s Degree in Business Engineering focused on production and logistics from the University of Leuven in Belgium. He completed his Masters in Science from the Louvain School of Management where is specialized in Supply Chain Management and International Business.

Manuela Valente

SVP - Chief People Officer  

Manuela Da Silva Valente is a seasoned Human Resources Executive with over 20 years experience working in international companies. Manuela has joined SOPHiA GENETICS in January 2019 from IQVIA (formerly Quintiles and IMS Health Inc.), a Human Data Science company, where she held a number of senior Human Resources roles with most recently the position of Global Senior Human Resources Director. Prior to this, she worked for several years at Outcome Sciences, where she successfully established the European operations and led the organization through the acquisition by Quintiles, a Global Clinical Research Organization.
Manuela obtained a Bachelor Degree in Business Administration from the Business Management School of Zurich and a Management & Human Resources Diploma from CEFCO Lausanne.
Manuela has extensive experience in aligning people strategies with business objectives and driving significant organizational and cultural changes, by focusing on talent development and employee engagement.

Daan Van Well

General Counsel  

Daan van Well is a legal professional with more than 20 years of experience in top tier private practice, in-house and consulting roles, and has extensive experience in legal, governance and compliance matters. Prior to joining SOPHiA GENETICS in June 2019, he was the Head of Legal at PwC in Geneva, Switzerland. Daan has also held several in-house legal positions for international food retailer Ahold (currently Ahold-Delhaize). He started his career as a lawyer at international law firm Loyens & Loeff in Rotterdam, The Netherlands. Daan holds an LL.M in Dutch civil law from Utrecht University and an Executive MBA in Management and Corporate Finance from HEC Lausanne. His peers have called him driven and motivated to promote team-building environments.

Zhenyu Xu

SVP - Chief Technology Officer  

Dr. Zhenyu Xu is a genome scientist with a background in molecular and computational biology. He holds a Master’s degree from Cambridge University in computational biology, and obtained his PhD at the European Molecular Biology Laboratory (EMBL) where he focused on the transcriptome landscape of yeast. His PhD work systematically characterized the non-coding transcripts in yeast which lead to the unveiling that in a majority of cases, transcriptions are bidirectional. Dr. Xu is among the most experienced bioinformaticians worldwide in clinical NGS data analysis. He joined SOPHiA GENETICS in 2012 and is the leader of the technology team who developed SOPHiA – the universal technology for Data-Driven Medicine. The AI powers SOPHiA DDM®, an advanced SaaS analytics platform for clinical genomics, recognized and widely used in hundreds of hospitals across the world.

Sergei Yakneen

SVP - Chief Information Officer  

Dr. Sergei Yakneen is an accomplished leader, technologist, and scientific researcher who brings a wealth of experience in financial technology, e-commerce, and cancer research. He joined SOPHiA GENETICS in September of 2019 after most recently working at the European Molecular Biology Laboratory in Heidelberg, Germany. He graduated from the University of Toronto with a degree in Computer Science and Mathematics and completed his PhD in Genomics and Computer Science at Heidelberg University. Over the past 15 years he’s led the Product Development and Professional Services groups of fin-tech startups, and launched Amazon.com’s first Software Engineering organization in the Toronto area. He led the technical working group of the world’s largest international cancer genome analysis project, the Pan Cancer Analysis of Whole Genomes, and devised new methods for analysis of genomic data at scale. Since 2013 Sergei has been focused on bringing the power of large-scale distributed computing to bear down on some of the hardest problems in cancer research.

BOARD OF DIRECTORS

Antoine Duchateau

Chairman of the Board  

Antoine Duchateau is a successful entrepreneur. He started his career with IBM Belgium as software engineer and sales executive for the financial sector in Brussels, then in 1981 joined the British BIS Banking Systems Group (BIS) in London, a worldwide leader in core banking application software, as Managing Director for Europe, then Chief Operating Officer. In 1995 he founded Odyssey Financial Technologies (OFT), which became over the years, the worldwide leader in mid-front office application software for the private banking sector. Under his direction as CEO and Chairman the company revenue grew to over $70M with 600 employees. In 2010, he executed the sale of Odyssey to Temenos Group AG. Following the sale of OFT, Antoine Duchateau decided to help start up and small to medium size enterprises by bringing his expertise. He was appointed Chairman of the Board of SOPHiA GENETICS in spring 2013.

Jurgi Camblong

CEO and Co-founder  

Dr. Jurgi Camblong is a visionary entrepreneur who is pioneering the Data-Driven Medicine movement around the world. He is a Molecular Biologist (published in Cell, Science & Nature), has a PhD in Life Sciences from the University of Geneva, and an EMBA in Management of Technology from EPFL/HEC Lausanne. In 2011, he founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz, and has since successfully been leading the development of the company, listed by the MIT Technology Review amongst the 50 smartest companies in 2017. Dr. Camblong is a member of the Advisory Council on Digital Transformation to the Swiss Federal Government, and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.  

Troy Cox

Board Member

Troy Cox is a pioneer in the precision medicine revolution. Former CEO of Foundation Medicine (FMI) - acquired by Roche in 2018 - Troy is today making a difference in patient’s lives by serving on corporate boards of innovative companies in the Biopharma, Diagnostic, and Tech industries. He is also committing his support to patient-focused non-profit organizations.
In June 2019, Troy joined SOPHiA GENETICS’ Board of Directors to help the organization further advance Data-Driven Medicine.
Prior to Foundation Medicine, Troy served as Senior Vice President and Officer at Genentech where he led US BioOncology for a period of unprecedented growth, participating in the launch of nearly half of the products from the world’s oncology leader. Other notable experiences include UCB, Sanofi-Aventis and Schering-Plough.
Troy’s expertise spans across strategy, general management, commercial, and R&D. His pharmaceutical career began as a Sales Representative after earning his MBA at the University of Missouri. He also received a BBA in Finance from the University of Kentucky.

Andrew Kanter

Board Member

Andrew Kanter is a Partner at Invoke Capital. Previously Mr Kanter served as Chief Operating Officer and General Counsel of Autonomy for twelve years, where he led its global legal and operations divisions and oversaw all major acquisitions and transactions. A qualified lawyer, Andrew was previously an attorney in private practice in San Francisco and London, specialising in venture capital, international M&A and corporate finance. He holds degrees from the University of Southern California Law Center and Johns Hopkins University.

Vincent Ossipow

Independent Board Member

Dr. Vincent Ossipow, CFA is Venture Partner at Omega Funds and brings 16 years of healthcare investment experience in public and private companies. Previously, Vincent worked with Sectoral Asset Management, a healthcare institutional investor, as a Partner for Private Equity. From 2000 to 2006 he worked as a research fellow at the University of Geneva on the molecular basis of brain function where he obtained a Ph.D. in molecular biology. Vincent trained as a postdoctoral fellow (Hoffman-La-Roche and Human Frontier Science Program fellow) in Geneva and at the National Cancer Institute NCI in Bethesda, Maryland, and completed a Certificate in International Finance and Global Markets at the Georgetown University School of Business in Washington, D.C.

Michael Schenck

Board Member  

Michael Schenck is an experienced venture capital and private equity investor and currently works with Alychlo, the investment firm of Belgian entrepreneur Marc Coucke.Previously, Michael was investment manager at Waterland Private Equity where he worked closely with a number of entrepreneurs to help realize their growth ambitions. He started his career in corporate finance in France and has worked both as a volunteer and entrepreneur in Africa. Michael holds Master’s Degrees in business and management from Erasmus University Rotterdam and HEC Paris.

James Wise

Board Member  

James is a partner at Balderton Capital, Europe’s largest venture fund focussed on growth stage technology companies. James works with companies in fields ranging from biotech, manufacturing, AR/VR and mobile, and has been an investor in companies acquired by Microsoft and Amazon. He holds board and advisory positions with 8 technology companies. Prior to Balderton, James helped launch one of the UK's first Social Impact Funds, and has worked for both the British Government and McKinsey & Company. He holds an MA Oxon from Oxford Univeristy.

Lilly Wollman

Board Member

Lilly joined Generation in 2015 and is the Co-Head of the Growth Equity strategy. Prior to joining Generation, Lilly was a Principal at The Baupost Group and a Director at Fortress Investment Group. Lilly began her career at Goldman Sachs in the Fixed Income, Currency and Commodities division. Lilly graduated magna cum laude and Phi Beta Kappa from Dartmouth College with a BA in Mathematics and a minor in Classics. She received an MBA from INSEAD and an MSc in Finance from London Business School. Lilly is a Board Member at SOPHiA GENETICS and Andela, and is a Board Observer at Cibo Technologies


ADVISORY BOARD

Lars Steinmetz

Professor of Genetics at Stanford University and Co-founder

Prof. Steinmetz is a leading scientist at the forefront of genomics research and technology development. He obtained his undergraduate degree from Yale University and a PhD in 2001 from Stanford University. At the age of 27, he started his own research group at the European Molecular Biology Laboratory (EMBL), with the aim to dissect the molecular events that lead from genotype to phenotype. In 2009, Dr. Steinmetz founded the department of Genome Biology at EMBL and became its first co-chair, which consists of over 100 scientists and 9 research teams. Since 2013, Dr. Steinmetz splits his time between EMBL and Stanford University, where he is Professor of Genetics at the School of Medicine and Co-Director of the Stanford Genome Technology Center at which he has led a research team since 2003. Dr. Steinmetz’s fundamental discoveries have led to insights into the genetic basis of complex traits ranging from model systems to humans. In addition to his academic endeavours, Dr. Steinmetz is a consultant and board member of several companies, advising in the areas of genetics and personalized medicine.

Peter Wild

Director of the Senckenberg Institute for Pathology (SIP), University Hospital of Frankfurt 

Dr. Wild, Peter J., MD, is the director of the Senckenberk Institute for Pathology (SIP) at the University Hospital of Frankfurt, and an Associate Professor at the Institute of Pathology and Molecular Pathology at the University Hospital of Zurich. He holds an academic rank of Professor of Systems Pathology form the University of Zurich. His research focuses on molecular genetics of solid tumors. He has successfully established NGS technologies for diagnostic molecular pathology, and organizes the Molecular Tumorboard Zurich (MTBZ). He completed his Pathology residency from the University of Regensburg, Hamburg-Eppendorf and Zurich in 2008. He has completed a postdoctoral training in Medical Biometrics at the University of Heidelberg, Germany. For a two-year postdoctoral training in cell biology, he joined the lab of Willy Krek at ETH Zurich. In April 2010 he also received his Venia Legendi in Pathology and initially worked as a senior physician at the Institute of Pathology and Molecular Pathology at the University Hospital of Zurich. He receives funding for research from the European Commission (H2020, PrECISE), Oncosuisse and the Swiss National Science Foundation. He has been honored with various awards during his training and career, including the Rudolf-Virchow-Prize of the German Society of Pathology in 2013. Dr. Wild has co-authored more than 155 articles in peer-reviewed journals.

Pierre Hutter

Chief Scientific Officer and Co-founder  

Dr. Pierre Hutter is one of the most renowned medical geneticists in Switzerland. He completed his PhD in genetics in Edinburgh and his postdoctoral work in Cambridge (UK). He discovered the landmark speciation gene Hmr (Hybrid male rescue) in Drosophila, which has become the most studied gene in the field of reproductive isolation. Between 2005 and 2011 he was co-director of the Geneva University laboratory of Predictive Oncology, one of the two reference laboratories for the study of cancer predisposition. As head of the Medical Genetics Service of the Valais hospital, Dr. Hutter was involved in the development of genetic diagnoses based on high-throughput sequencing, works as a consultant for a private laboratory, and is an expert of accreditation of molecular genetics laboratories. He represents the Swiss Society of Medical Genetics at the FAMH commission of the Swiss Academy of Medical Sciences.

Jan O. Korbel

Group Leader at EMBL Heidelberg

Dr. Jan O. Korbel is a groupleader at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, in the Genome Biology Unit. He has a PhD in Molecular Biology and performed his Postdoc at Yale University. He leads several major consortium projects and works on more than 10 organizing committees and programs in Europe and the US. In the last two years he was elected member of the German National Academy of Sciences Leopoldina, received the Manfred-Fuchs-Award for work on self-regulation in science, and the Chica and Heinz Schaller Research Award for biomedical research achievements. He is also in the „40 under 40“ list of the journal “Cell” and member of the Cancer Research UK “Science Committee”, responsible for the oversight and development of UK’s principal basic & translational cancer research program. He has published 76 papers indexed in PubMed, of which 17 are in Nature, Science or Cell, and works as an Ad hoc peer-reviewer of the highest scientific journals.